The health care spending debate in our country raises the following questions: How much spending is too much? What percent of gross domestic product should go to health care? How can the value of the health care dollar be maximized? As stakeholders wrestle with these questions, significant attention is often paid to the portion of spending attributable to various sectors of the health care system. The Trump administration has focused heavily on prescription medicines. 

As health care stakeholders engage in public dialogue on this topic and consider policies for managing prescription drug spending, there is a need for sound data to inform the discussions. How much are we spending on drugs? If you ask a multi-stakeholder panel of health care leaders, you’ll likely hear a range of responses, from a low of 10% to a high of nearly 30%. If stakeholders are unable to agree on a number, they are unable to even begin to agree on a policy. Can these seemingly irreconcilable responses be reconciled? The answer is yes! This interactive webinar explained the underlying differences in these estimates and attendees learned how to address them in a collaborative and evidence-based policy discussion.

Learning Objectives

At the conclusion of the session, participants will be able to:

  • Review publicly reported estimates of drug spending
  • Explore underlying methodological inputs that drive variation in estimates of prescription drug spending
  • Consider methodological approaches that are appropriate for the health spending policy questions at hand

Watch Recorded Webinar

Speaker List



Michael Kleinrock headshot

Michael Kleinrock, M.A.

Research Director - IQVIA Institute for Human Data Science

Michael Kleinrock serves as research director for the IQVIA Institute for Human Data Science. Read Bio


Robert W. Dubois headshot
Author, Presenter

Robert W. Dubois, M.D., Ph.D.

Chief Science Officer and Executive Vice President - National Pharmaceutical Council (NPC)

Robert W. Dubois is the chief science officer and executive vice president of the National Pharmaceutical Coun... Read Bio